Fraunhofer ITEM: News

Press Release / 1.9.2026

Animal-Free Chemical Testing

Fraunhofer ITEM is driving new approaches to risk assessment.

Press Release / 24.8.2026

EU Project BRISA Launched

An international consortium is developing solutions to detect, reduce and prevent hazardous airborne pollutants in industry. 

Press Release / 3.8.2026

Work safety in hair salons

Fraunhofer ITEM uses an innovative non-animal testing method to investigate the effects of aerosols from heated hair products.

 

Fraunhofer ITEM Events: 

Fraunhofer CIMD Symposium "RNA-Based Therapeutics"
September 22-23, 2026 | Fraunhofer ITEM, Hannover

Webinar #2: Development of an Inhalable Anti-infective – From Bench to Bedside
September 29, 2026 | online

Conferences: 

Eurotox Conference
 September 13. - 16, 2026 | Vienna

Press Release / 1.6.2026

Improving the Availability of mRNA-Based Drugs

RNAuto project enables accelerated production and manufacturing.

Press Release / 12.3.2026

Rocket Launch for StellarHeal

Milestone for Future Wound Care in Space Flights and on Earth.

For more than four decades, we have been developing solutions for human health

 

Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

 

Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.

 

RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

 

Stem cell technologies

Applying stem cell technologies and differentiated cell types for safety and efficacy testing.

Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.

 

Toxicology

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

Project archive

Here you can find more projects sorted by our research and development competences. 

Our services

 

Drug Development

 

Translational Biomedical Engineering

From idea to safe medical device:

 

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of more than 70 institutes of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research.

With a focus on respiratory research, the R&D portfolio at our Hannover headquarters comprises three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

 

More information about Fraunhofer ITEM